Steven Naprawa, MD
Psychiatry · Syracuse, NYNPI 1669436341
Payments from drug & device makers
Across 1,114 payments — averaging $503.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$533K
- AbbVie$24K
- Alkermes, Inc.$787
- Teva Pharmaceuticals USA, Inc.$617
- Johnson & Johnson$614
- Otsuka America Pharmaceutical, Inc.$417
- plus $2K from 13 others
What the payments were for
- Consulting fees$25,1284%
- Speaking & faculty fees$471,99684%
- Travel & lodging$42,6318%
- Food & beverage$20,7514%
- Education$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 807 | $532,695 |
| AbbVie(2 entities) | 95 | $23,700 |
| Alkermes, Inc. | 49 | $787 |
| Teva Pharmaceuticals USA, Inc. | 30 | $617 |
| Johnson & Johnson | 20 | $614 |
| Otsuka America Pharmaceutical, Inc. | 16 | $417 |
| E.r. Squibb & Sons, L.L.C. | 18 | $335 |
| Sunovion Pharmaceuticals Inc. | 21 | $320 |
| Vanda Pharmaceuticals Inc. | 11 | $251 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $194 |
| Axsome Therapeutics, Inc. | 7 | $167 |
| Lundbeck LLC | 8 | $152 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $122 |
| Indivior Inc. | 5 | $89 |
| Supernus Pharmaceuticals, Inc. | 4 | $54 |
| Corium, LLC | 3 | $43 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$519,628
- VRAYLAR$20,033
- INVEGA SUSTENNA$146
- INVEGA TRINZA$146
- COBENFY$122
- AUSTEDO$114
- INVEGA$112
- REXULTI$104
How this compares
$560,607 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 26 | $195,192 |
| AustedoDeutetrabenazine | 20 | $157,560 |
| Invega SustennaPaliperidone Palmitate | 45 | $114,728 |
| Invega TrinzaPaliperidone Palmitate | 12 | $96,935 |
| VraylarCariprazine Hcl | 44 | $72,300 |
| Abilify MaintenaAripiprazole | 24 | $64,629 |
| AristadaAripiprazole Lauroxil | 12 | $38,288 |
| Aripiprazole | 79 | $5,657 |
| Varenicline Tartrate | 15 | $5,492 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 45 | $5,276 |
| Ziprasidone Hcl | 34 | $3,159 |
| Divalproex Sodium ErDivalproex Sodium | 41 | $2,097 |
| Olanzapine | 82 | $1,979 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $1,904 |
| Bupropion XlBupropion Hcl | 63 | $1,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $614 | $211,66257 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $532,695 | $195,19226 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $617 | $157,56020 claims |
| AbbVieVraylar | $23,700 | $72,30044 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $417 | $64,62924 claims |
| Alkermes, Inc.Aristada | $787 | $38,28812 claims |
| Almatica Pharma LLCSertraline Hcl | $13 | $784142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Syracuse
- Ahmed NizarSyracuse$763K
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.